Position
Renaissance Technologies in Neumora Therapeutics, Inc.
Back to the book · All holders of NMRA
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$315.6K$1.95 → $1.70
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 1.45M | $2.59M | — | — | — | 0.0% |
| Q1 2026 | 1.39M | $2.71M | $1.95 | $222.2K | −$101.9K | 0.0% |
| Q2 2026 | 1.26M | $2.15M | $1.70 | −$315.6K | −$247.1K | 0.0% |